Gefitinib for refractory advanced non-small-cell lung cancer.
Moriguchi
Hisashi
H
Kim
Tae-You
TY
Sato
Chifumi
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000235:genetics; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011799:Quinazolines / Q000627:therapeutic use*; D012907:Smoking / Q000009:adverse effects*; D015996:Survival Rate
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib